Evidence map›Paper›PMID 31744224›Full record

ArticleCancers2019

Sensitive and Specific Detection of Ewing Sarcoma Minimal Residual Disease in Ovarian and Testicular Tissues in an In Vitro Model.

Laure Chaput, Victoria Grèze, Pascale Halle, Nina Radosevic-Robin, Bruno Pereira, Lauren Véronèse, Hervé Lejeune, Philippe Durand, Guillaume Martin, Sandra Sanfilippo and 4 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Laure ChaputBiologie et Médecine de la Reproduction, AMP (Assistance Médicale à la Procréation), CECOS (Centre d'Etude et de la Conservation des Oeufs et du Sperme), CHU (Centre Hospitalier Universitaire) Estaing, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France.ORCID 0000-0002-2362-3062
Victoria GrèzeService d'Hématologie et d'Oncologie Pédiatrique, CHU Estaing, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
Pascale HalleCentre de Biothérapie d'Auvergne, CHU Estaing, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
Nina Radosevic-RobinLaboratoire de Biologie Médicale (LBM) OncoGenAuvergne, Unité Pathologie, Centre Jean Perrin (CLCC de la région Auvergne), 63011 Clermont-Ferrand, France.ORCID 0000-0002-1633-8730
Bruno PereiraDélégation à la Recherche Clinique et l'Innovation, Unité de Biostatistiques, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.ORCID 0000-0003-3778-7161
Lauren VéronèseImagerie Moléculaire et Stratégies Théranostiques Faculté de Médecine, Unité INSERM 1240, Université Clermont Auvergne, 63001 Clermont Ferrand, France.
Hervé LejeuneService de Médecine de la Reproduction, Hôpital Femme Mère Enfant, Hospices Civils de Lyon, 69003 Lyon, France.
Philippe DurandKallistem, Ecole Normale Supérieure de Lyon, 69007 Lyon, France.
Guillaume MartinKallistem, Ecole Normale Supérieure de Lyon, 69007 Lyon, France.
Sandra SanfilippoBiologie et Médecine de la Reproduction, AMP (Assistance Médicale à la Procréation), CECOS (Centre d'Etude et de la Conservation des Oeufs et du Sperme), CHU (Centre Hospitalier Universitaire) Estaing, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France.
Michel CanisService de Gynécologie, CHU Estaing, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.ORCID 0000-0003-0852-7811
Justyna KanoldService d'Hématologie et d'Oncologie Pédiatrique, CHU Estaing, CHU Clermont-Ferrand, 63000 Clermont-Ferrand, France.
Andrei TchirkovImagerie Moléculaire et Stratégies Théranostiques Faculté de Médecine, Unité INSERM 1240, Université Clermont Auvergne, 63001 Clermont Ferrand, France.
Florence BrugnonBiologie et Médecine de la Reproduction, AMP (Assistance Médicale à la Procréation), CECOS (Centre d'Etude et de la Conservation des Oeufs et du Sperme), CHU (Centre Hospitalier Universitaire) Estaing, CHU Clermont-Ferrand, 63003 Clermont-Ferrand, France.
Inserm · FRCentre Hospitalier Universitaire de Clermont-Ferrand · FRÉcole Normale Supérieure de Lyon · FRUniversité Claude Bernard Lyon 1 · FR

Funding

Ligue Contre le Cancer No grant number
6 · The paper itself

Abstract

Ewing sarcoma (EWS) is a common pediatric solid tumor with high metastatic potential. Due to toxic effects of treatments on reproductive functions, the cryopreservation of ovarian tissue (OT) or testicular tissue (TT) is recommended to preserve fertility. However, the risk of reintroducing residual metastatic tumor cells should be evaluated before fertility restoration. Our goal was to validate a sensitive and specific approach for EWS minimal residual disease (MRD) detection in frozen germinal tissues. Thawed OT (

Indexed as

Ewing sarcomafertility preservationminimal residual disease detectionovarian tissueRT-qPCRtesticular tissue

Identifiers

PMID31744224
PMCPMC6895895
OpenAlexW2983474715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.